Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous process, conolidine modulates alternate molecular targets. A Science Developments examine observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://jeanm009xwu9.law-wiki.com/user